Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Tirzepatide and Retatrutide — mechanism, dosing, side effects, legal status, and pricing.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It represents a new class of dual-incretin therapy with superior weight-loss efficacy compared to single-agonist approaches.
Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is in Phase 3 clinical trials for obesity and type 2 diabetes and has demonstrated the highest weight loss of any anti-obesity medication tested to date.
Tirzepatide
Retatrutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
The SURMOUNT-1 trial demonstrated average weight loss of 22.5% at the highest dose over 72 weeks, surpassing semaglutide. HbA1c reductions were also superior in head-to-head trials. Cardiovascular outcome trials are ongoing.
The Phase 2 trial demonstrated up to 24.2% body weight loss at 48 weeks at the highest dose (12 mg), exceeding results of both semaglutide and tirzepatide. Significant reductions in hepatic steatosis (fatty liver) were also observed. Phase 3 trials are ongoing with results expected in 2025–2026. Eli Lilly is the developer.
Key references
Tirzepatide and Retatrutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs